Anticipated $-0.59 EPS for REGENXBIO Inc. (RGNX) on May, 8

April 17, 2018 - By Theresa Judd


On May, 8 WallStreet anticipated REGENXBIO Inc. (NASDAQ:RGNX)’s earnings report, according to RTT. Analysts have expectation on stock’s EPS of $-0.59. That’s up 28.05 % from last year’s $-0.82 EPS. 15.69 % negative EPS growth is what analysts predict. $-0.51 EPS was revealed for last [previous quarter]. The stock increased 9.83% or $3.4 during the last trading session, reaching $38.REGENXBIO Inc. has 914,788 shares volume, 133.52% up from normal. RGNX is uptrending and has moved 43.49% since April 17, 2017. The stock outperformed the S&P500 by 31.94%.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease.The firm is valued at $1.21 billion. The Company’s gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.Last it reported negative earnings. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration.

REGENXBIO Inc. (NASDAQ:RGNX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.